Skip to main content

Table 4 Overall survival, progression-free survival and local control data

From: Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

 

Months ± SD (95% Confidence Interval)

Median OS

14 ± 5 (3–25)

Median PFS

14 ± 3 (8–20)

 

1-year (%)

2-year (%)

OS Rates

55

38

PFS Rates

56

27

Local Control Rates

79

51

  1. OS: Overall survival, PFS: Progression-free survival